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Heparin-based, injectable microcarriers for
controlled delivery of interleukin-13 to the brain†
Lucas Schirmer,a Chloé Hoornaert,b Debbie Le Blon,b,c Dimitri Eigel,a Catia Neto,d
Mark Gumbleton,d Petra B. Welzel,a Anne E. Rosser,e,f Carsten Werner, a,g
Peter Ponsaertsb,c and Ben Newland *a,d
Interleukin-13 (IL-13) drives cells of myeloid origin towards a more
anti-inflammatory phenotype, but delivery to the brain remains
problematic. Herein, we show that heparin-based cryogel micro-
carriers load high amounts of IL-13, releasing it slowly. Intra-stria-
tal injection of loaded microcarriers caused local up-regulation of
ARG1 in myeloid cells for pro-regenerative immunomodulation in
the brain.
In the event of damage to the central nervous system (CNS),
pro-inflammatory immune cells infiltrate the injured tissue to
fend off infections and clear cellular debris. The resulting
inflammation can add to the detrimental effects of a variety of
different neuroinflammatory conditions, including ischemic
stroke,1 multiple sclerosis,2,3 spinal cord injury,4 and
epilepsy.5
Microglia, the resident immune cells of the CNS, adapt to
these pathological changes in their environment by altering
their phenotype, morphology, and their functions; towards the
inflammatory M1 polarization state. Similar to macrophages,
which can also be found in the CNS parenchyma, they can
exist in a range of phenotypes that orchestrate the immune
response in the region.6 However, alternative activation of
microglia and macrophages can change their phenotype
towards a regenerative polarization state (M2) and thus
promote tissue regeneration. As major players in the regulation
of inflammation/tissue repair, these regenerative microglia
and macrophages, offer a promising target for therapeutic
intervention in neuroinflammatory diseases.
One strategy to shift the polarization balance, is the admin-
istration of the known M2-inducing cytokine, interleukin-13
(IL-13).2,3 This anti-inflammatory cytokine, produced predomi-
nantly by Th2 lymphocytes, can inhibit the secretion of pro-
inflammatory signaling mediators such as IL-1β, IL-6, IL-12,
and TNF-α, while enhancing the expression of the mannose
receptor and MHC II molecules.7 In addition, IL-13 has been
shown to suppress the infiltration of inflammatory cells and to
decrease axonal loss.8 Previous studies have demonstrated the
potential of IL-13-based immunomodulation of microglia/
macrophages towards an anti-inflammatory/pro-regenerative
phenotype in the rodent CNS, which might be utilized as a
promising therapeutic strategy for a range of inflammatory dis-
eases such as multiple sclerosis, spinal cord injury, and
stroke.1,2,4,5,9 Despite this cytokine’s pronounced therapeutic
potential, delivery to the CNS so far remained challenging.
The major limitation lies in the low long-term stability of
most cytokines due to degradation and proteolysis under phys-
iological conditions,10 which requires some form of continu-
ous delivery for effective therapeutic application. Implantable
infusion catheters have been developed for direct, sustained
delivery of neurotrophic factors to the brain of Parkinson’s
patients.11 However, their application is limited by the
increased risk of infections and other possible side effects
such as hemorrhages or neurological complications.12
Besides the direct delivery of protein therapeutics,
increased levels of the desired protein in the brain can also be
achieved through viral vector-mediated overexpression or
transplantation of cells engineered to secrete the therapeutic
of interest.1,2,4,5,9 While gene-based delivery has been shown to
be effective in supplying IL-13 to the target region, these
methods often suffer from low transfection efficiency, variable
durability of gene expression, possible mutations due to gene
integration, and, in some cases, adverse immune
reactions.13–15 As a viable alternative, an injectable protein
delivery system that allows local sustained release of IL-13
could provide a less invasive and safer approach to modulate
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the immune response within a specific region of the brain. To
the best of our knowledge, no delivery device for sustained
IL-13 release has yet been developed.
Biomaterial-based approaches, such as encapsulation of
proteins within polymer microparticles, represent a promising
strategy for protein delivery to the brain.16 Polymers such as
poly (lactic-co-glycolic) acid (PLGA) have been previously
employed to release glial cell line-derived neurotrophic factor
(GDNF) to the rodent and primate brain for therapeutic appli-
cations in Parkinson’s disease.17,18 A drawback of most micro-
encapsulation approaches is the limited control over payload
release, which is often characterized by an initial diffusion-
controlled burst release phase within the first day.18 Another
problem associated with microencapsulation arises due to low
protein stability within the microparticle, resulting in a loss in
protein bioactivity.19 Thus, many microparticles are less than
ideal vehicles for the therapeutic delivery of signaling
mediators such as IL-13.19,20
As a viable alternative, soft biohybrid hydrogels containing
glycosaminoglycans (GAGs) have been extensively used in
order to biomimetically emulate functions of the extracellular
matrix.21 Through their negative charge, sulfated GAGs such
as heparin can interact with a range of growth factors, chemo-
kines, and cytokines. Positively charged binding sites found
on the protein’s surface allow for electrostatic complexation
and stabilization against proteolytic or thermal degradation.
Incorporation of heparin into hydrogel networks, therefore,
becomes a highly appealing strategy for the loading and sus-
tained delivery of therapeutic proteins.22–28
Here, as an alternative to conventional hydrogels, we
explore heparin-based macroporous cryogel microparticles
(microcarriers) for sustained delivery of IL-13 into the brain.
Macroporous cryogels have a unique sponge-like structure,
which gives them several advantages over other biomaterials.
Their compressibility, and their ability to reshape to their orig-
inal size afterward, make them ideal for micro-invasive injec-
tion where they conform to the void space.30,31 Furthermore,
their very high surface area to volume ratio facilitates electro-
static loading with proteins or other drugs.29
The presented study set out to prove whether injectable
microscale hydrogel scaffolds, containing heparin as a build-
ing block and affinity center, could act as a sustained delivery
device to polarize macrophages and microglia towards the pro-
regenerative M2 phenotype in the brain. Cryogel microcarriers
were thus prepared, characterized, and optimized for their
interaction and release of IL-13. The immunomodulatory
effects of IL-13 functionalized microcarriers were then
assessed: first on bone marrow-derived macrophages in vitro
and then in the murine brain in vivo (Fig. 1).
Design and characteristics of cryogels
Macroporous cryogels were formed using water as a porogen,
by combining an emulsion technique with cryogelation of the
aqueous heparin and poly(ethylene glycol) precursor solution
at subzero temperatures.32 Under these conditions, the
polymerization occurs in the non-frozen microphase between
the ice crystals, creating robust struts and a porous structure.33
Fig. 2 shows the macroporous structure of the microcarriers in
the dry state (scanning electron microscopy image, Fig. 2A)
and in the PBS swollen state (confocal laser scanning fluo-
rescence microscopy image, Fig. 2B). The cross-section
obtained via a single z-plane image (ESI Fig. S1†) shows that
the microcarrier consists of thin struts and macropores and
that the majority of the cross-sectional area is large open
pores. Further analysis of the architecture through compu-
tational feature extraction and modeling demonstrated the
Fig. 1 Schematic overview of the experimental approach. Heparin-
based microcarriers were used to load and release IL-13 in order to
change the phenotype of macrophages in vitro and induce a pro-regen-
erative phenotype in macrophages/microglia in the mouse brain.
Fig. 2 Microcarriers have a macroporous structure. (A) Representative
scanning electron microscope image of a dry microcarrier. (B)
Representative 40 µm z-projection (z-stack) of an ATTO 647 labeled
microcarrier in phosphate-buffered saline visualized by confocal
microscopy. (C) Computationally generated model of a pore network
within a microcarrier. (D) Size distribution of microcarriers. (E) Pore size
distribution within the microcarriers.
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high interconnectivity of the pores throughout the hydrogel
matrix (Fig. 2C). Characterization of the microcarriers using
confocal microscopy showed an average diameter of 321 µm
(±131 µm) (Fig. 2D) and pore size of 23.4 µm (±11.3 µm)
(Fig. 2E).
The macroporous structure of cryogels allows them to be
compressed to a small volume fraction of their original size yet
retain “shape memory” and re-form to their original size and
shape when the deforming force is removed.29–31,34 Cryogel
materials can adsorb large amounts of energy without experi-
encing a large increase in stress. Consequently, these rather
soft materials are very tough: we previously showed that they
do not even break at a compression strain of over 90%.29 This
ability to compress and expand is useful for applications
where biomaterial-assisted delivery of cells or therapeutics
through a small cannula size is required (i.e., stereotactic injec-
tion into the central nervous system).35 We tested the ability of
microcarriers to be injected through a 30 gauge needle or a
glass capillary (internal diameters of 160 and 140 µm respect-
ively). ESI Fig. S2† shows the compression of a single microcar-
rier (420 µm diameter) through the glass capillary (com-
pression ratio of 66%) with no visible change in microcarrier
structure after injection.
Biofunctionalization of cryogels with
IL-13
While the heparin-binding affinity of other similar 4-helical
interleukins such as IL-4 has been well reported,36–39 there is
rather limited experimental data about the heparin-affinity of
IL-13. In silico modelling of the interaction of heparin with
IL-13, based on the work of Mottarella et al.40 and Kozakov
et al.41 helped to identify multiple potentially heparin-binding
domains as previously described by Mulloy et al.42 (Fig. 3A and
ESI Video S1†).
The computational results were confirmed by the results of
the IL-13 loading experiments, wherein microcarriers where
incubated with either 100 ng or 500 ng IL-13. Analysis of the
supernatants after 24 h revealed that at both loading concen-
trations, the microcarriers were able to take up nearly all of the
IL-13 out of the solution, i.e., >95% of the IL-13 was bound to
the microcarriers (Fig. 3C). Further analysis of the IL-13
loading, utilizing Atto-647 labeled protein, showed an accumu-
lation of the IL-13 within the hydrogel matrix of the microcar-
riers (Fig. 3B). IL-13 fluorescence accumulated within the
cryogel struts until reaching a maximum after 13 h (ESI
Fig. S3†). Due to their strong affinity for IL-13, the microcar-
riers could be loaded with high amounts of IL-13 (a maximum
of 500 ng mg−1 of microcarrier was tested) and the release of it
into a buffer solution containing 1% bovine serum albumin
was therefore expected to be slow and sustained.
Fig. 3D shows that IL-13 was indeed released without an
initial burst for at least 21 days (longest time tested). For
microcarriers loaded with 100 ng of IL-13 per mg of microcar-
rier, 9.3% of the IL-13 was released by day 7, continuing to
10.4% by day 21 (9.3 ng and 10.4 ng released respectively). The
500 ng mg−1 of microcarrier group released 12% of the IL-13
by day 7 and 15.9% by day 21 (71.9 ng and 79.5 ng released
respectively). Although the chosen set-up does not fully recapi-
tulate the complex in vivo environment (where multiple blood
components, extracellular fluid, and other ECM components
may competitively bind to the heparin to displace the IL-13), it
gives us an indication that heparin-based cryogel microcarriers
have the potential for therapeutic sustained IL-13 delivery.
With up to 85% of the IL-13 remaining on the microcarriers,
further release can be envisaged through displacement by
extracellular molecules in vivo. By utilizing the strong affinity
of IL-13 via binding sites on the AB loop and helix D42 to extra-
cellular matrix glycosaminoglycans, such as heparin, a con-
trolled, sustained release of IL-13 from the scaffold over
several weeks could be achieved. Furthermore, protection of
the protein load by the heparin-based hydrogel against degra-
dation has been shown previously for the structurally similar
4-helical protein IL-4.43
Immunomodulatory activity of IL-13
functionalized cryogels on bone-
marrow derived macrophages
In vitro tests with mouse bone marrow-derived macrophages
were performed to assess if IL-13 released from the microcar-
riers could induce polarization of macrophages towards the
alternatively activated (M2) state. It has been well established
that they respond to IL-13 in vitro.44 Furthermore, it has been
Fig. 3 Heparin-based microcarriers bind and release IL-13. (A)
Representative image of the in silico modeling of the electrostatic inter-
action of IL-13 (green) with the heparin biopolymer (orange). (B)
Confocal laser microscope images of microcarriers (green) which take
up IL-13 labeled with Atto-647 (red) within 24 hours. Scale bars =
100 µm. (C) For 100 or 500 ng of IL-13 per mg of microcarrier in the
loading solution, 97.9% and 99.94% of the IL-13 were bound to the
microcarriers, respectively. (D) IL-13 was released for up to three weeks
(longest time tested) (n = 3 for all experiments and error bars represent
± standard deviation).
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well-characterized that alternative M2 activation of murine
macrophages induces the upregulation of Arg1 and Ym1 signa-
ture genes.45 Fig. 4A shows a schematic depiction of the
process of loading 1 mg microcarriers in a solution (200 µL)
containing either 100 ng or 500 ng of IL-13, followed by the
washing step and placement of the microcarriers in culture
with the macrophages. Subsequent gene expression analysis
showed that IL-13 loaded microcarriers (at both loading con-
centrations) caused a major upregulation of the M2 marker
genes Arg1 (Fig. 4B) and Ym1 (Fig. 4C). The expression levels
were similar to that obtained when IL-13 was directly added
into the macrophage medium as a positive control (IL-13 in
solution group). Control microcarriers that were not loaded
with IL-13 (empty microcarrier group) caused no increase in
the expression of either Arg1 or Ym1, indicating that the micro-
carriers themselves do not affect the expression of these genes.
As this cell culture experiment was carried out for three days,
approximately 5–10 ng of IL-13 should have been released into
the macrophage medium from the microcarriers loaded with
100 ng mg−1 (deduced from the release experiment data,
Fig. 3D). This was below the concentration of IL-13 in the
soluble IL-13 positive control group (10 ng mL−1) but was still
enough to induce strong upregulation of both genes.
Immunomodulatory activity of IL-13
functionalized cryogels in the brain
A delivery system that slowly releases IL-13 in the CNS could be
utilized for a variety of applications. Since any injection into
the brain results in a needle stick injury, whereby macrophages
and microglia invade the injection tract (an event which is
seen even when injecting only sterile saline46), such a sus-
tained-release system could be used as an adjuvant for regen-
erative medicine and cell transplantation strategies. The micro-
glial/macrophage response associated with the stereotactic
injection is typically pro-inflammatory in nature,9,47 adding a
greater burden to the brain region undergoing treatment. In
the example of cell replacement therapies, the host brain can
become a hostile environment for transplanted cells,48,49 and
the rapid death of grafted cells post-transplantation may, in
part, be due to this adverse response.50–52 The microcarrier-
based IL-13 delivery system may therefore provide a suitable
platform technology for modulating the host response to
implanted cells, viral vectors, or other therapeutics. To this
end, an in vivo study was performed whereby either empty
microcarriers or IL-13 loaded microcarriers were stereotacti-
cally administered to the adult mouse striatum.
The host response to injection of empty versus IL-13 loaded
microcarriers was analyzed and compared with the contralat-
eral side of the brain that received no injection (Fig. 5A, micro-
carrier regions outlined with a dashed line). GFAP+ astrocytes
(astrocytic scar) migrated to the border but did not really infil-
trate either empty or IL-13 loaded microcarriers (Fig. 5B). In
contrast, IBA1+ reactive microglia could be observed surround-
ing and invading the microcarrier-injected area. This pattern
of host response is very similar to that observed when grafting
cells into the rodent brain, where the cell graft becomes encap-
sulated by an astrocytic scar and infiltrated and surrounded by
cells of myeloid origin.51,53 Quantification of the GFAP+ and
IBA1+ cells through immunohistochemistry is shown in
Fig. 5C and D, respectively, where no significant difference in
the area of staining could be observed between empty and
IL-13 loaded microcarriers. This illustrates that the IL-13 itself
is not exacerbating the host glial scar or microglial response.
To analyze the microglia/macrophage infiltration of the
microcarrier injection site, F4/80 immunohistochemical ana-
lysis (general myeloid activation marker) was performed in
conjunction with major histocompatibility class II (MHC II).
The injection sites of empty microcarrier were predominantly
infiltrated by F4/80+ cells, with just a small fraction of the cells
showing dual F4/80 and MHC II staining. Interestingly, F4/80+
MHC II+ double-positive cells were restricted to regions sur-
rounding blood vessels, indicating their monocytic origin.
IL-13 loaded microcarriers, on the other hand, displayed an
infiltration by F4/80+ MHC II+ double-positive macrophages.
This latter infiltration pattern is reminiscent of mesenchymal
stem cell grafts, where IBA1+ MHCII+ macrophages predomi-
nantly infiltrate the cell graft while IBA1+ MHCII− resident
microglia accumulate in the graft border.54 Furthermore, a sig-
nificant fraction of immune cells that infiltrated the IL-13
loaded microcarrier injection sites, but not empty microcarrier
sites, were positive for ARG1 expression. This suggests that the
IL-13 released from the microcarriers is able to alternatively
activate either the resident microglia or the peripheral macro-
phages. We have previously shown, via injection of cells engin-
eered to overexpress IL-13, that the phenotypic shift towards
Fig. 4 IL-13 released from microcarriers induces alternative activation
of macrophages in vitro. (A) Schematic depiction of the experimental
process of microcarrier loading with IL-13 and testing their effect on
inflammatory macrophages. Gene expression analysis showed that IL-13
loaded microcarriers caused an upregulation of alternative activation
polarization markers Arg1 (B) and Ym1 (C) (n = 3, one-way ANOVA with
Tukey’s post-hoc analysis ns = no significant difference, * represents a
P-value ≤ .05, ** represents a P-value ≤ .01).
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the pro-regenerative ARG1+ M2a phenotype is predominantly
observed in macrophages rather than microglia,4 hence con-
firming the monocytic origin of IBA1+ ARG1+ cells infiltrating
the graft as well as the microglial origin of IBA1+ ARG1+ cells
found in the injection site border.
With the emergence of high-throughput, high-precision
techniques such as single-cell RNA sequencing, the high com-
plexity and dynamism of microglial and macrophage pheno-
types are becoming ever more apparent.55 Since these cells’
primary function consists of immune surveillance of their sur-
roundings, they are well-adapted to respond to a plethora of
local cues that convey information regarding potential infec-
tions and/or tissue damage. Among these, toll-like receptor
ligands (e.g., LPS or dsRNA) and pro-inflammatory cytokines
(e.g., IL1β and TNF) will cause a shift to a more inflammatory
phenotype,56 whilst the Th2 cytokines IL-4, IL-10 and
IL-13 have been shown to drive more anti-inflammatory
phenotypes.57,58 It is therefore conceivable that these interleu-
kins could be utilized to enhance the regenerative capacity of
the central nervous system by inducing endogenous repair.
Fig. 5 IL-13 released from microcarriers induces alternative activation of macrophages in vivo. Histological analyses were performed one week
after in vivo delivery of empty microcarriers (empty MC) (n = 3) or IL-13-loaded microcarriers (IL-13 MC) (n = 4). (A) Immunofluorescent staining for
GFAP + astrocytes, IBA1 + myeloid cells, F4/80 + MHCII− activated microglia, F4/80 + MHCII+ activated macrophages, and ARG1 + M2 polarized
myeloid cells. MC injection area is outlined with a dashed line where MC = microcarrier, and T = brain tissue. The white arrow indicates the location
of a blood vessel, scale bars = 100 µm. (B–D) Quantification of the relative surface area that stained positive for the markers GFAP (B), IBA1(C), or
ARG1(D). Data points represent mean per condition (IL = ipsilateral, CL = contralateral), with error bars representing ± standard deviation. A
Student’s t-test was performed to analyze statistically significant differences between empty and IL-13 loaded microcarriers (ns = no significant
difference, ** represents a P-value ≤ .01).
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Even so, the transient nature of the phenotypic shift would
likely necessitate a constant supply of the cytokine of interest.
Poor protein stability in vivo due to proteolytic degradation
has driven the development of infusion pumps, such as those
used for continued growth factor delivery to the brain.11
Alternatively to direct protein infusion, both gene and cell
therapeutic approaches could be considered. We previously
showed that injection of IL-13 encoding lentiviral vectors, as
well as transplantation of IL-13 expressing carrier cells in the
CNS, resulted in a local and sustained production of
IL-13.1,2,4,9,59 Despite the advantages of both approaches, viral
strategies still pose a safety concern (resulting from excessive
TLR activation of CNS microglia/macrophages in response to
the viral particles) whereas cell-mediated approaches are not
without drawbacks, in particular graft rejection or uncon-
trolled cell growth/death.1
We herein proposed an alternative approach, showing that
microscale biomaterial constructs give a slow and sustained
release of IL-13 and cause ARG1 over-expression for at least
seven days following intra-striatal injection. Thus, we could
demonstrate that biomaterial-based delivery systems can be
used to modulate the host inflammatory response, which
could impact future surgical interventions in the brain without
the need for cell (and subsequent immunosuppression) or
viral gene delivery through a single infusion for relatively acute
mediation.
Further work is warranted to determine the loaded cryogel
storage capabilities, the full duration of IL-13 release, long-
term host responses to the microcarriers (with and without the
payload), and whether similar results can be achieved with
other immunomodulatory factors such as IL-4.
Conclusions
Herein, we report on the synthesis of microscale cryogels
(microcarriers) comprised of heparin and four-arm PEG, and
on the analysis of their suitability as a sustained delivery
system for the immunomodulatory cytokine IL-13. 1 mg of
these microcarriers could be loaded with at least 500 ng of
IL-13 and released 13% of the cytokine over a period of three
weeks without a significant burst release in the first few hours.
IL-13 functionalized microcarriers caused overexpression of
ARG1 (anti-inflammatory phenotype marker) both in macro-
phages cultured in vitro, and in microglia/macrophages of the
brain in vivo. This study proves the concept that injectable
cryogel microcarriers, utilizing heparin to non-covalently
complex IL-13, can deliver the cytokine to the CNS and thus
modulate the local immune response towards a pro-regenera-
tive M2 polarization.
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